[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100465130":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":29,"centralContacts":33,"locations":39,"responsibleParty":56,"collaborators":58,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":37,"eligibilityCriteria":68,"healthyVolunteers":69,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":37,"studyType":76,"phases":77,"briefSummary":80,"conditions":81,"keywords":84,"overallStatus":41,"whyStopped":37,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Massachusetts General Hospital","OTHER",[8],{"label":9,"type":10,"description":9,"interventionNames":11},"Cognitively Normal Subjects and ADRD subjects","EXPERIMENTAL",[12,13],"Diagnostic Test: PET\u002FMR Imaging","Drug: 64Cu-FBP8",[15,22],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","PET\u002FMR Imaging","PET\u002FMRI Scan with \\[64Cu\\]FBP8 as directed by protocol",[9],[21],"Positron Emission Tomography\u002FMagnetic Resonance Imaging",{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","64Cu-FBP8","Will be administered by intravenous injection by bolus by a qualified nuclear medicine technician at the Martinos Center",[9],[28],"Positron Emission Tomography dye",[30],{"name":31,"affiliation":5,"role":32},"Ciprian Catana, MD, PhD","PRINCIPAL_INVESTIGATOR",[34],{"name":31,"role":35,"phone":36,"phoneExt":37,"email":38},"CONTACT","617-643-4885",null,"ccatana@mgh.harvard.edu",[40],{"facility":5,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"RECRUITING","Boston","Massachusetts","02115","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-71.05977,42.35843,{"lat":51,"lon":50},[54,55],{"name":31,"role":35,"phone":36,"phoneExt":37,"email":38},{"name":31,"role":32,"phone":37,"phoneExt":37,"email":37},{"type":32,"investigatorFullName":31,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":37,"oldOrganization":37},"Principal Investigator",[59],{"name":60,"class":61},"National Heart, Lung, and Blood Institute (NHLBI)","NIH","100465130","phase-1-assess-fibrin-in-brains-with-adadrd-100465130",false,"NCT05336695","Assess Fibrin in Brains With AD\u002FADRD","Assess the Brain Levels of Fibrin in Alzheimer's Disease and Its Related Dementias Subjects Using 64Cu-FBP8 PET","Inclusion Criteria:\n\n* Age between 55 and 90 years\n* Ability to provide informed consent\n* Specific to healthy volunteers: no history of ADRD\n* Specific to ADRD subjects: clinical diagnosis of AD - either amnestic or atypical, clinical severity ranging from MCI to moderate dementia (CDR 0.5-2.0), MMSE score greater than or equal to 15 and\u002For MOCA greater than or equal to 12\n* Specific to BAnD subjects: referred through the Brain Aging and Dementia (BAnD) research registry\n\nExclusion Criteria:\n\n* MR contraindications such as: electrical implants such as cardiac pacemakers or perfusion pumps; ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos near the eye, or steel implants, ferromagnetic objects such as jewelry or metal clips in clothing\n* Preexisting medical conditions including a likelihood of developing seizures or claustrophobic reactions, and any greater than normal potential for cardiac arrest\n* Subjects whose estimated glomerular filtration rate (eGFR) \\\u003C 60 mL\u002Fmin will be excluded from receiving the gadolinium-based contrast agent\n* Research-related radiation exposure exceeding current Massachusetts General Hospital (MGH) Radiology Department guidelines (i.e. 50 millisievert in the prior 12 months)\n* 3\\. In line with published MGH IRB guidelines for pregnancy must be ruled out by urine ß-HCG if answers to screening questions suggest that pregnancy is possible and if female participants are premenopausal and of child-bearing age. Subjects will not be able to enroll if they are breastfeeding.",true,"ALL","55 Years","90 Years",{"count":74,"type":75},30,"ESTIMATED","INTERVENTIONAL",[78,79],"PHASE1","PHASE2","The goal of this project is to quantify brain fibrin content using 64Cu-FBP8-PET in the brains of subjects ranging from cognitively normal to clinically diagnosed with ADRD to evaluate potential regional differences.",[82,83],"Alzheimer Disease","Dementia of Alzheimer Type",[82,85],"Dementia","2025-10-28",{"date":88,"type":89},"2025-10-30","ACTUAL",{"date":91,"type":89},"2022-03-29",{"date":93,"type":75},"2026-09-28",{"name":5,"class":6},1]